Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Furmonertinib, Furmonertinib 160mg, Drug: Furmonertinib
furmonertinib, daily · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| furmonertinib 240 mg | EXPERIMENTAL | - |
| furmonertinib 160 mg | EXPERIMENTAL | - |
| platinum-based chemotherapy | ACTIVE_COMPARATOR | carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously |
| Name | Type | Description |
|---|---|---|
| furmonertinib 240 mg oral, daily | DRUG | furmonertinib tablet |
| furmonertinib 160 mg oral, daily | DRUG | furmonertinib tablet |
| platinum-based chemotherapy | DRUG | (carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV) |
Key Inclusion Criteria: * Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. * Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion...
Top 20 of 84 competitors
Furmonertinib is an investigational small molecule being developed for non-small cell lung cancer (NSCLC), including metastatic disease. It is studied in patients with EGFR exon 20 insertion mutations and in advanced EGFR mutant NSCLC with uncleared ctDNA. It is not yet approved and remains in clinical development.
Furmonertinib is a kinase inhibitor, as indicated by its '-tinib' suffix. It is being studied in NSCLC patients with EGFR exon 20 insertion mutations, suggesting it targets the epidermal growth factor receptor (EGFR) pathway. The drug is administered orally at doses including 80 mg, 160 mg, and 240 mg daily.
Furmonertinib is being developed by ArriVent BioPharma, Inc., a biopharmaceutical company traded under the ticker AVBP. The company is conducting clinical trials for this investigational drug in non-small cell lung cancer.
Furmonertinib is in Phase 2 clinical development, with active trials including a Phase 2 study in advanced EGFR mutant NSCLC. It has received Breakthrough Therapy designation from the FDA. The drug is investigational and has not been approved for any use.
Furmonertinib is being studied in several trials, including NCT04858958 (Phase 1, NSCLC with exon 20 insertion), NCT05334277 (Phase 2, EGFR mutant NSCLC with uncleared ctDNA), NCT05466149 (Phase 2, NSCLC with EGFR exon 20 insertion), and NCT05607550 (Phase 3, FURVENT, comparing to chemotherapy in metastatic NSCLC).
Furmonertinib is also known by its dosage forms, including Furmonertinib 80 mg, 160 mg, and 240 mg oral daily. These names refer to the same drug compound. No other alternative names have been disclosed.